FPA 144

Drug Profile

FPA 144

Alternative Names: FPA144

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Five Prime Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Immunostimulants; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gastric cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 19 Dec 2017 Five Prime Therapeutics and Zai Lab agree to co-promote and co-develop FPA 144 in China (including Taiwan, Hong Kong, and Macau) for Gastric cancer
  • 30 Nov 2017 Phase-I clinical trials in Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, First-line therapy) in USA (IV) (NCT03343301)
  • 06 Nov 2017 Five Prime Therapeutics plans the phase I/III FIGHT trial for Gastric and Oesophageal cancer (First-line therapy, Combination therapy, Metastatic disease) in Japan and World in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top